What is Mabt?
Mid-Atlantic BioTherapeutics (Mabt) is a biotechnology firm dedicated to developing novel treatments for debilitating neurological and infectious diseases, including Alzheimer's, Parkinson's, and ALS. The company recently expanded its pipeline by acquiring XPose Therapeutics, bolstering its focus on breakthrough oncology treatments for difficult-to-treat cancers. Mabt integrates biotechnology with artificial intelligence to create therapies that address critical unmet medical needs and enhance patient outcomes. Established in 2011, Mabt is driven by a commitment to compassionate innovation and improving lives through scientific discovery.
How much funding has Mabt raised?
Mabt has raised a total of $50M across 1 funding round:
Other Financing Round
$50M
Other Financing Round (2025): $50M with participation from Legend Innovators
Key Investors in Mabt
Legend Innovators
Legend Innovators, based in Bhubaneswar, Odisha, specializes in providing innovative business advisory services aimed at fostering sustainable growth for businesses of all sizes. Their core offerings include virtual CFO services, start-up mentoring, fund-raising services, and comprehensive business establishment support.
What's next for Mabt?
The substantial enterprise-level funding Mabt has garnered signals a pivotal growth phase, likely enabling the company to accelerate its research and development initiatives, expand its clinical trial operations, and further integrate its recent acquisition. This strategic investment is expected to propel Mabt's mission to deliver transformative therapies for neurological, infectious, and oncological conditions, reinforcing its position in the competitive biotech landscape.
See full Mabt company page
